Singapore, April 18 -- China SXT Pharmaceuticals, Inc., a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces ("TCMPs").

The company has announced that it has entered into securities purchase agreements and other ancillary agreements with certain institutional investors pursuant to which China SXT will sell:

(1) Senior Convertible Notes in the aggregate principal amount of $15 million (each, a "Note" and collectively, the "Notes"), consisting of (i) a Series A Note in the principal amount of $10 million, and (ii) a Series B Note in the principal amount of $5 million.

(2) Series A and Series B warrants (the "Warrants") to purchase such amount of ...